Ghent University Academic Bibliography

Your filters: cql: author="van Dam, Pieter-Jan" or (type any "bookEditor issueEditor" and editor="van Dam, Pieter-Jan")

Add to list
- Conference Paper
- C3
Toward methodology for comprehensive androgen receptor splice variant profiling in cell-free RNA from patients with metastatic prostate cancer

Jan Vanwelkenhuyzen (UGent) , Pieter-Jan van Dam, Katleen De Preter (UGent) , Johan Lindberg, Piet Ost (UGent) and Bram De Laere (UGent)

(2022) Belgian Association for Cancer Research, 2022 Annual meeting, Abstracts.
Add to list
Can medical imaging identify the histopathological growth patterns of liver metastases?

Emily Latacz, Pieter-Jan van Dam, Christian Vanhove (UGent) , Laura Llado, Benedicte Descamps (UGent) , Núria Ruiz, Ines Joye, Dirk Grünhagen, Steven Van Laere, Piet Dirix, et al.

(2021) SEMINARS IN CANCER BIOLOGY. 71. p.33-41
Add to list
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen, Vibeke Kruse (UGent) , Jurgen Corthals, Kelly Schats, Pieter-Jan van Dam, Teofila Seremet, Carlo Heirman, Lieve Brochez (UGent) , Mark Kockx, Kris Thielemans, et al.

(2020) CANCER IMMUNOLOGY IMMUNOTHERAPY. 69(12). p.2589-2598
Add to list
- Conference Paper
- C3
Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer : preliminary results

Peter Van Dam, Yannick Verhoeven, Jorrit De Waele, Julie Jacobs, Pieter-Jan Van Dam, Mark Kockx, Koen Van de Vijver (UGent) , Martin Lammens, An Wouters, Evelien Smits, et al.

(2020) JOURNAL OF CLINICAL ONCOLOGY. 38(15).
Add to list
- Journal Article
- A1
- open access
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, et al.

(2019) CLINICAL CANCER RESEARCH. 25(6). p.1766-1773
Add to list
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Bram De Laere, Prabhakar Rajan, Henrik Gronberg, Luc Dirix, Johan Lindberg, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, et al.

(2019) JAMA ONCOLOGY. 5(7). p.1060-1062
Add to list
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, et al.

(2018) PROSTATE. 78(6). p.435-445
Add to list
- Journal Article
- A1
- open access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, et al.

(2018) GENOME MEDICINE. 10.

Academic Bibliography

Toward methodology for comprehensive androgen receptor splice variant profiling in cell-free RNA from patients with metastatic prostate cancer

Can medical imaging identify the histopathological growth patterns of liver metastases?

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer : preliminary results

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Contents

Support

Contact